Ulcerative Colitis, Active Moderate
6
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
17%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
TD-1473 for Active Ulcerative Colitis (UC)
Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis
Adacolumn in Refractory UC Patients Trial